Appendix Table 3.
Clinical Characteristics of MrOS Sleep Participants by BIS2 eGFR Category
| BIS2 eGFR category (mL/min/1.73m2)
|
||||||
|---|---|---|---|---|---|---|
| Baseline Characteristics | Overall (N= 2994) |
≥75 (N= 517) |
60 to 74 (N= 1217) |
45 to 59 (N= 943) |
<45 (N= 317) |
p-value |
| Age, years, mean (SD) | 76.4 (5.6) | 72.8 (4.1) | 75.3 (4.7) | 78.4 (5.4) | 80.6 (6.1) | <0.001 |
| Race/Ethnicity, n (%) | <0.001 | |||||
| White | 2696 (90) | 441 (85) | 1099 (90) | 875 (93) | 281 (89) | |
| Black | 109 (4) | 24 (5) | 41 (3) | 30 (3) | 14 (4) | |
| Other | 189 (6) | 52 (10) | 77 (6) | 38 (4) | 22 (7) | |
| Education, n (%) | <0.001 | |||||
| Less than high school | 160 (5) | 21 (4) | 52 (4) | 51 (5) | 36 (11) | |
| High school | 472 (16) | 79 (15) | 160 (13) | 182 (19) | 51 (16) | |
| College/grad school | 2362 (79) | 417 (81) | 1005 (83) | 710 (75) | 230 (73) | |
| Body mass index, kg/m2, mean (SD) | 27.2 (3.8) | 26.6 (3.4) | 27.2 (3.8) | 27.3 (3.9) | 27.7 (4.3) | <0.001 |
| Appendicular lean mass, kg, mean (SD) | 23.9 (3.5) | 24.2 (3.4) | 24.2 (3.4) | 23.8 (3.4) | 23.2 (3.6) | <0.001 |
| Total body lean mass, kg, mean (SD) | 56.3 (7.1) | 56.5 (7.0) | 56.7 (7.1) | 56.1 (7.1) | 55.4 (7.4) | 0.014 |
| Smoking, n (%) | ||||||
| Never | 1183 (40) | 200 (39) | 486 (40) | 379 (40) | 118 (37) | 0.471 |
| Past | 1750 (58) | 312 (60) | 703 (58) | 541 (57) | 194 (61) | |
| Current | 59 (2) | 5 (1) | 27 (2) | 22 (2) | 5 (2) | |
| Self-rated health good/excellent, n (%) | 2596 (87) | 474 (92) | 1082 (89) | 797 (85) | 243 (77) | <0.001 |
| Hypertension*, n (%) | 1894 (63) | 256 (50) | 674 (55) | 673 (71) | 291 (92) | <0.001 |
| Diabetes*, n (%) | 402 (13) | 60 (12) | 148 (12) | 119 (13) | 75 (24) | <0.001 |
| Self-reported stroke, n (%) | 110 (4) | 12 (2) | 35 (3) | 39 (4) | 24 (8) | <0.001 |
| Self-reported coronary heart disease**, n (%) | 765 (26) | 83 (16) | 262 (22) | 292 (31) | 128 (41) | <0.001 |
| Self-reported congestive heart failure, n (%) | 181 (6) | 12 (2) | 47 (4) | 70 (7) | 52 (16) | <0.001 |
| Self-reported peripheral vascular disease, n (%) | 291 (10) | 22 (4) | 91 (8) | 116 (13) | 62 (20) | <0.001 |
| Alcohol intake, drinks/week, n (%) | <0.001 | |||||
| 0–2 | 1761 (59) | 260 (51) | 674 (56) | 599 (64) | 228 (72) | |
| 3–13 | 1048 (35) | 215 (42) | 457 (38) | 298 (32) | 78 (25) | |
| 14+ | 168 (6) | 38 (7) | 81 (7) | 39 (4) | 10 (3) | |
| CKD-EPIcr,cys eGFR, mean (SD) | 69.8 (17.1) | 93.6 (5.9) | 76.4 (5.9) | 58.6 (5.7) | 39.1 (7.4) | <0.001 |
| BIS2 eGFR, mean (SD) | 62.4 (13.6) | 82.3 (6.4) | 67.1 (4.2) | 53.5 (4.1) | 38.7 (5.9) | <0.001 |
| CKD-EPIcys eGFR, mean (SD) | 67.8 (19.8) | 96.1 (8.9) | 74.6 (9.1) | 54.4 (7.3) | 35.7 (7.5) | <0.001 |
| CKD-EPIcr eGFR, mean (SD) | 70.7 (14.9) | 87.1 (6.8) | 76.7 (7.9) | 63.0 (8.7) | 43.8 (9.5) | <.001 |
| Follow up time, years, mean (SD) | 7.3 (1.9) | 7.7 (1.4) | 7.5 (1.7) | 7.1 (2.1) | 6.2 (2.5) | <0.001 |
Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; cr, creatinine; cysc, cystatin c; eGFR, estimated glomerular filtration rate; BIS2, Berlin Initiative Study Equation 2
*
As determined by self-report or any disease-specific medication use
**
Coronary heart disease includes myocardial infarction, coronary artery bypass grafting, and angioplasty